Resistance to antimicrobials in zoonosis-producing bacteria remains high in animals and humans
According to the report published on 27 February, 2018 by the European Food Safety Agency (EFSA) and the European Center for Disease Prevention and Control (ECDC), bacteria present in humans and animals are still showing resistance to antimicrobials. The report highlights several emerging problems and confirms antimicrobial resistance as one of the most significant threats for public health, as it reduces the effectiveness of available treatment options.
Among the new findings, based on 2016 data, the report points to the identification of carbapenem-resistant Escherichia coli in fowl, an antibiotic that is not authorized for use in animals; presence of linezolid in methicillin-resistant Staphylococcus aureus in pigs, and extended-spectrum-beta-lactamase-producing Salmonella Kentucky, with high ciprofloxacin resistance in humans. These findings are alarming as the above antibiotics are used in human to treat severe infections.
To deal with this situation, EFSA proposes the use of alternative treatments, including probiotics, for animal feed.
PROBISEARCH is a leader in the development and application of microbiological, immunological, metagenomic, transcriptomic, metabolomic and / or proteomic techniques to the study of complex microbiotas, such as those found in various human and animal mucosa and epithelia. The application of these techniques sheds light on the microbial diversity and its influence on the host, both in normal conditions and after the application of any type of treatment (antibiotics, probiotics …) or in pathological situations. To this end, PROBISEARCH multidisciplinary team is involved in the different development stages, including the microbiological and immune analysis the samples, to allow for the collection of scientific evidence on the effectiveness of our strains.
Probisearch is located in Madrid’s Technology Park. Founded in 2011 by a group of scientists from the Complutense University of Madrid, its mission is to offer new probiotic alternatives to prevent and treat various human and veterinary diseases associated with the microbiota
Probisearch was acquired in 2016 by biotechnology group CZV- Biofabri with the aim of persevering in this mission, as well as integrating this knowledge and experience within a more comprehensive offering in the field of probiotics for human and animal health.